257 related articles for article (PubMed ID: 16421902)
1. Effects of human monoclonal antibody 216 on B-progenitor acute lymphoblastic leukemia in vitro.
Bieber MM; Twist CJ; Bhat NM; Teng NN
Pediatr Blood Cancer; 2007 Apr; 48(4):380-6. PubMed ID: 16421902
[TBL] [Abstract][Full Text] [Related]
2. In vitro validation of gamma-secretase inhibitors alone or in combination with other anti-cancer drugs for the treatment of T-cell acute lymphoblastic leukemia.
De Keersmaecker K; Lahortiga I; Mentens N; Folens C; Van Neste L; Bekaert S; Vandenberghe P; Odero MD; Marynen P; Cools J
Haematologica; 2008 Apr; 93(4):533-42. PubMed ID: 18322257
[TBL] [Abstract][Full Text] [Related]
3. Antibody-producing human-human hybridomas. III. Derivation and characterization of two antibodies with specificity for human myeloid cells.
Andreasen RB; Olsson L
J Immunol; 1986 Aug; 137(3):1083-90. PubMed ID: 3459756
[TBL] [Abstract][Full Text] [Related]
4. Elimination of clonogenic tumor cells from human bone marrow using a combination of monoclonal antibody:ricin A chain conjugates.
Bregni M; De Fabritiis P; Raso V; Greenberger J; Lipton J; Nadler L; Rothstein L; Ritz J; Bast RC
Cancer Res; 1986 Mar; 46(3):1208-13. PubMed ID: 3510720
[TBL] [Abstract][Full Text] [Related]
5. Functional and phenotypic upregulation of CD13/aminopeptidase-N on precursor-B acute lymphoblastic leukemia after in vitro stimulation.
Makrynikola V; Favaloro EJ; Browning T; Bianchi A; Bradstock KF
Exp Hematol; 1995 Oct; 23(11):1173-9. PubMed ID: 7556527
[TBL] [Abstract][Full Text] [Related]
6. IMC-EB10, an anti-FLT3 monoclonal antibody, prolongs survival and reduces nonobese diabetic/severe combined immunodeficient engraftment of some acute lymphoblastic leukemia cell lines and primary leukemic samples.
Piloto O; Nguyen B; Huso D; Kim KT; Li Y; Witte L; Hicklin DJ; Brown P; Small D
Cancer Res; 2006 May; 66(9):4843-51. PubMed ID: 16651440
[TBL] [Abstract][Full Text] [Related]
7. Anti-GD3 monoclonal antibody analysis of childhood T-cell acute lymphoblastic leukemia: detection of a target antigen for antibody-mediated cytolysis.
Reaman GH; Taylor BJ; Merritt WD
Cancer Res; 1990 Jan; 50(1):202-5. PubMed ID: 2403416
[TBL] [Abstract][Full Text] [Related]
8. A unique antigen expressed on myeloid cells and acute leukemia blast cells defined by a monoclonal antibody.
Ball ED; Graziano RF; Fanger MW
J Immunol; 1983 Jun; 130(6):2937-41. PubMed ID: 6574189
[TBL] [Abstract][Full Text] [Related]
9. Antitumor activity of a monoclonal antibody against CD47 in xenograft models of human leukemia.
Uno S; Kinoshita Y; Azuma Y; Tsunenari T; Yoshimura Y; Iida S; Kikuchi Y; Yamada-Okabe H; Fukushima N
Oncol Rep; 2007 May; 17(5):1189-94. PubMed ID: 17390064
[TBL] [Abstract][Full Text] [Related]
10. CD45 monoclonal antibody-mediated cytolysis of human NK and T lymphoma cells.
Wulf GG; Boehnke A; Chapuy B; Glass B; Hemmerlein B; Schroers R; Brenner MK; Truemper L
Haematologica; 2006 Jul; 91(7):886-94. PubMed ID: 16818275
[TBL] [Abstract][Full Text] [Related]
11. Mapping of binding epitopes of a human decay-accelerating factor monoclonal antibody capable of enhancing rituximab-mediated complement-dependent cytotoxicity.
Guo B; Ma ZW; Li H; Xu GL; Zheng P; Zhu B; Wu YZ; Zou Q
Clin Immunol; 2008 Aug; 128(2):155-63. PubMed ID: 18502181
[TBL] [Abstract][Full Text] [Related]
12. Defucosylated humanized anti-CCR4 monoclonal antibody KW-0761 as a novel immunotherapeutic agent for adult T-cell leukemia/lymphoma.
Ishii T; Ishida T; Utsunomiya A; Inagaki A; Yano H; Komatsu H; Iida S; Imada K; Uchiyama T; Akinaga S; Shitara K; Ueda R
Clin Cancer Res; 2010 Mar; 16(5):1520-31. PubMed ID: 20160057
[TBL] [Abstract][Full Text] [Related]
13. Reactivities of mouse monoclonal antibody K2.7 to renal cancers in complement dependent cytotoxicity and antibody dependent cell-mediated cytotoxicity.
Kinouchi T; Bander NH; Kotake T
J Urol; 1995 Jul; 154(1):288-92. PubMed ID: 7776448
[TBL] [Abstract][Full Text] [Related]
14. Lysis of human tumor cell lines by canine complement plus monoclonal antiganglioside antibodies or natural canine xenoantibodies.
Helfand SC; Hank JA; Gan J; Sondel PM
Cell Immunol; 1996 Jan; 167(1):99-107. PubMed ID: 8548851
[TBL] [Abstract][Full Text] [Related]
15. Immunotoxin-mediated elimination of clonogenic tumor cells in the presence of human bone marrow.
Uckun FM; Ramakrishnan S; Houston LL
J Immunol; 1985 Mar; 134(3):2010-6. PubMed ID: 3855433
[TBL] [Abstract][Full Text] [Related]
16. Myeloid precursors and acute myeloid leukemia cells express multiple CD33-related Siglecs.
Nguyen DH; Ball ED; Varki A
Exp Hematol; 2006 Jun; 34(6):728-35. PubMed ID: 16728277
[TBL] [Abstract][Full Text] [Related]
17. Ex vivo-activated human macrophages kill chronic lymphocytic leukemia cells in the presence of rituximab: mechanism of antibody-dependent cellular cytotoxicity and impact of human serum.
Lefebvre ML; Krause SW; Salcedo M; Nardin A
J Immunother; 2006; 29(4):388-97. PubMed ID: 16799334
[TBL] [Abstract][Full Text] [Related]
18. Serological study for in vitro use of monoclonal antibody for autologous bone marrow transplantation in null cell-type acute lymphocytic leukemia.
Sao H; Morishima Y; Ueda R; Yoshikawa S; Kodera Y; Ohno R; Takahashi T
Jpn J Cancer Res; 1985 Dec; 76(12):1212-21. PubMed ID: 3937833
[TBL] [Abstract][Full Text] [Related]
19. Histone deacetylase inhibitor treatment downregulates VLA-4 adhesion in hematopoietic stem cells and acute myeloid leukemia blast cells.
Mahlknecht U; Schönbein C
Haematologica; 2008 Mar; 93(3):443-6. PubMed ID: 18268283
[TBL] [Abstract][Full Text] [Related]
20. Normal and malignant human myelocytic and monocytic cells identified by monoclonal antibodies.
Bernstein ID; Andrews RG; Cohen SF; McMaster BE
J Immunol; 1982 Feb; 128(2):876-81. PubMed ID: 6948042
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]